(MedPage Today) — An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic castration-resistant prostate cancer…
Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/115713
Author :
Publish date : 2025-05-22 13:41:00
Copyright for syndicated content belongs to the linked Source.
